Immune Therapeutics, Inc. (AIMT) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry Into A Material Definitive Agreement.
On October 25, 2016 Immune Therapeutics, Inc. and Acromax
Dominicana, SA entered into a five year contract for
manufacturing of LDN tablets, capsules and/or creams. The
agreement is attached hereto as Exhibit 10.1 and incorporated by
reference.
On October 31, 2016 Immune Therapeutics, Inc. and its wholly
owned subsidiary TNI BioTech International, Ltd. on the one hand
and GB Pharma Holdings, LLC on the other amended and replaced
their exclusive agency agreement dated June 12, 2014 and
appointed GB Pharma Holdings, LLC as the exclusive agent for
Immune Therapeutics, Inc. in accordance with the terms of the
October 31, 2016 agreement. The agreement is attached hereto as
Exhibit 10.2 and incorporated by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are filed herewith.
| Exhibit No. | Description | |
| 10.1 |
Contract for the Manufacturing of Pharmaceutical Products between Immune Therapeutics, Inc. and Acromax Dominicana, SA |
|
| 10.2 |
Exclusive Agency Agreement between Immune Therapeutics, Inc., TNI BioTech International, Ltd. and GB Pharma Holdings, LLC |
About Immune Therapeutics, Inc. (AIMT)
